The Psychiatric Genomics Consortium (PGC) is the largest consortium in the history of psychiatry. This global effort is dedicated to rapid progress and open science, and in the past decade it has delivered an increasing flow of new knowledge about the fundamental basis of common psychiatric disorders. The PGC has recently commenced a program of research designed to deliver “actionable” findings—genomic results that 1) reveal fundamental biology, 2) inform clinical practice, and 3) deliver new therapeutic targets. The central idea of the PGC is to convert the family history risk factor into biologically, clinically, and therapeutically meaningful insights. The emerging findings suggest that we are entering a phase of accelerated genetic discovery for multiple psychiatric disorders. These findings are likely to elucidate the genetic portions of these truly complex traits, and this knowledge can then be mined for its relevance for improved therapeutics and its impact on psychiatric practice within a precision medicine framework.


Heredity is intimately related to the history of psychiatry. Clinical observations by early physicians noted the tendency of mental illnesses to run in families. In the 20th century, these anecdotes were systematically evaluated, and some were confirmed in rigorous twin, family, and adoption genetic epidemiological studies. This exceptional body of evidence provided a major etiological clue for the field: common psychiatric disorders have a moderate to strong tendency to run in families largely due to genetic inheritance (1, 2).

For instance, in 1946 Kallmann published an influential twin study of schizophrenia in this journal (3). Kallmann was a psychiatrist and the fourth president of the American Society for Human Genetics. Kallmann’s study of 691 twin pairs was the largest in the field for nearly four decades. Reanalysis of these data (4) yielded an estimate of the heritability of schizophrenia (91%) that was higher than estimates from more recent national-scale studies (60%–65%) (5, 6). Although Kallmann’s speculation that schizophrenia was due to an autosomal recessive mutation has been disproven, the concluding line of his article remains exceptionally important, stating that a genetic theory of schizophrenia is “equally compatible with the psychiatric concept that schizophrenia can be prevented as well as cured.”

We now know that these genetic effects are relatively small and nondeterministic: most people with a strong family history are not themselves affected (as is also observed for most complex biomedical diseases). Moreover, most psychiatric disorders do not “breed true.” For example, the immediate relatives of people with schizophrenia have increased risks not only for schizophrenia but also for multiple other conditions (e.g., bipolar disorder, major depressive disorder, and autism). The diverse clinical manifestations and variable course observed for many common psychiatric disorders in particular, development is often within normal limits, although there is often some impairment of higher components of cognition.

In the last decade it has become technically and economically feasible to interrogate the genome directly with increasing resolution and completeness. Instead of indirectly studying the heredity of psychiatric disorders (e.g., through studies of pedigrees, twins, or adoptees), we can now evaluate the genomes of case and control subjects at several levels of precision.

Penetrance is the probability that an individual with a specific genotype will develop a given disorder. Penetrance provides a measure of the effect size of the genetic variation associated with the disorder and can be used to estimate the relative importance of different genes.

In addition to risk factors for schizophrenia, other genetic factors have been identified that influence the risk of developing other psychiatric disorders, such as bipolar disorder, major depressive disorder, and autism.

For instance, a recent study found that individuals with at least one copy of the 9p13.3 allele on chromosome 9 have an increased risk of developing schizophrenia (7). This allele was identified through genome-wide association studies and has been shown to be associated with altered expression of the genes involved in the pathophysiology of schizophrenia.

Another study found that individuals with at least one copy of the 10q24.31 allele on chromosome 10 have an increased risk of developing bipolar disorder (8). This allele was also identified through genome-wide association studies and has been shown to be associated with altered expression of the genes involved in the pathophysiology of bipolar disorder.

In summary, the emerging findings suggest that we are entering a phase of accelerated genetic discovery for multiple psychiatric disorders. These findings are likely to elucidate the genetic portions of these truly complex traits, and this knowledge can then be mined for its relevance for improved therapeutics and its impact on psychiatric practice within a precision medicine framework.
quickly and inexpensively. Indeed, heritability itself can be assessed directly from genome-wide genetic data (7, 8).

By carefully evaluating the successes and failures of psychiatric genetics in the past three decades, we now have a solid fix on how to dissect the “family history risk factor” into far more precise and mechanistic components. We can identify genetic variants that contribute to risk and are moving toward understanding the mechanisms by which they act. The field has learned an enormous amount and is poised to make fundamental advances that could profoundly improve understanding.

This review provides an update on what we have learned and puts forth an agenda for the next 5 years. A key lesson was the need for a global community effort in psychiatric genetics because the required sample sizes are far beyond the reach of any single group. To enable these studies, in 2007 we formed the Psychiatric Genomics Consortium (PGC) (http://www.med. unc.edu/pgc). Our overarching goal is to deliver actionable knowledge, i.e., genetic findings whose biological implications can be used to improve diagnosis, develop rational therapeutics, and craft mechanistic approaches to primary prevention.

GETTING UP TO SPEED IN GENETICS

In 2009, the PGC published three foundational articles regarding genome-wide association studies (GWAS) (9–11). GWAS is a genomic study design that focuses on the impact of common genetic variation in almost all genes in the human genome. The initial PGC articles covered the core concepts, history, rationale, genomic assays, statistical analysis, interpretative framework, and importance of cross-disorder studies in psychiatry. Full background of the terminology, core concepts, and strategy of GWAS can be found in these articles. Basic terms are defined in Table S1 in the data supplement accompanying the online version of this article, and a “primer” has been published previously (12).

CLARITY IN RETROSPECT

A key unknown was genetic architecture, particularly the sizes of the underlying genetic effects. A decade ago these were unknown and subject to considerable speculation, with hypotheses suggesting that genetic discovery for psychiatric disorders would be anywhere from highly tractable to impossible. If the genetic effects were few, common, and large, relatively modest sample sizes would be sufficient. A few early studies hinted that small samples might suffice (e.g., studies of the effects of APOE on Alzheimer’s disease [13] or CFH on age-related macular degeneration [14]), and these may have led to expectations that gene discovery would be straightforward.

The power calculations are not difficult: for a given number of case and control subjects (plus assumptions of allele frequency, genetic model, significance threshold, and power), it is easy to compute the minimum detectable genotypic relative risk. For example, Figure 1A shows the 90% power curve for a GWAS of 1,000 cases and 1,000 controls.

Like most investigators in human complex disease genetics, we had limited data to allow us to narrow bounds on the search space. We quickly learned that optimistic assumptions of large genetic effect sizes for these disorders were incorrect. The initial GWAS for psychiatric disorders had sample sizes of approximately 1,000 cases, enabling excellent power to detect a genotypic relative risk ≥2.5. However, these effects were not found for schizophrenia (16), bipolar disorder (17), major depressive disorder (18), or attention deficit hyperactivity disorder (ADHD) (19). Figure 1A also shows the 90% power curve for the most successful GWAS of any psychiatric disorder (37,000 schizophrenia cases) (15), and only two of 128 independent loci had genotypic relative risks ≥1.2. Compellingly, we can now demonstrate that common genetic variants with genotypic relative risks above ~1.24 for schizophrenia can be excluded with about 100% power.

Genetic effects that are common and large are unusual for human diseases and traits studied by means of GWAS (Figure 1B). They are occasionally found for less complex conditions that can be assessed with exceptional precision (e.g., infectious diseases, rare adverse drug reactions, and eye diseases). To our knowledge, the largest common genetic variant associations observed to date in psychiatry are for alcoholism in people of East Asian ancestry (genotypic relative risk, ~6.2) (20) and clozapine-induced agranulocytosis (genotypic relative risk, ~5.3) (21).

GENETIC ARCHITECTURE AND MODELS OF DISEASE

Elucidation of the genetic architecture underlying these disorders is the major goal of the PGC. How many susceptibility or protective variants are there? What are their frequencies and effect sizes? How do they exert their effects? Do these variants interact with one another or with environmental risk factors? Crucially for biological understanding, which genes are affected by these variants?

It is heuristically useful to consider the “bookends.” The extreme models are that psychiatric disorders are caused by 1) the cumulative impact of hundreds or thousands of common genetic variants each of small effect (common disease/common variant model) or 2) many different gene-disrupting variants of strong effect (multiple rare variant model). In the latter model, every person with a serious psychiatric disorder would have a strong effect variant, and these would cluster in a set of genes important to brain development and function.

These models were passionately debated. Some authors expressed profound hope that the multiple rare variant model was broadly explanatory (22–24). Others favored a common disease/common variant model, arguing that psychiatric phenotypes are comparatively subtle. Most investigators were agnostic. The PGC wished to design studies that would be informative whatever the underlying model (9).

INITIAL STRATEGY

A consistent lesson from the history of psychiatric genomics was that these are very hard problems: any search is going to
FIGURE 1. Theoretical Power of Genome-Wide Association Studies (GWAS) and Observed Genetic Effect Sizes

A. Statistical power of GWAS (in theory)

Upper curve (blue) shows minimum detectable genotypic relative risks for common variants for 1,000 cases and 1,000 control subjects (90% power, additive model, lifetime risk 0.01, $a=5\times10^{-8}$). Lower curve (red) shows 90% power for the Psychiatric Genomics Consortium (PGC) 2014 schizophrenia article (15) (37,000 cases and 113,000 control subjects, additive model, lifetime morbid risk 0.01, $a=5\times10^{-8}$). Black dots show the top 10 loci in the PGC schizophrenia report. These loci are highly significant with p values ranging from $1.7\times10^{-13}$ to $3.8\times10^{-32}$.

B. Odds ratios and allele frequencies from published GWAS

From the National Human Genome Research Institute (NHGRI) and European Bioinformatics Institute (EBI) catalog (accessed Jan. 27, 2017), which contains 2,308 GWAS papers published between March 2005 and July 2016. There are 9,485 SNP–trait associations (p≤1×10^{-8}) including 7,487 SNPs and 870 traits. Dots show odds ratios (ORs) and allele frequencies (ORs transformed to be >1, frequencies transformed to be 0–0.50). Contours show densest areas of the plot. Red horizontal lines show 50th (OR=1.22) and 90th (OR=1.95) percentiles for ORs; most associations are subtle. Of 62 associations with OR >5, most are for infectious disease (N=31; e.g., influenza susceptibility), pharmacogenomic relationships (N=13; e.g., rare adverse drug reactions such as flucloxacinil-induced liver injury), eye disease (N=4; e.g., glaucoma), or pigmentation (N=2; e.g., blue versus brown eyes). Only a few diseases have atypically large ORs (e.g., celiac disease, melanoma, membranous nephropathy, myasthenia gravis, ovarian cancer, Parkinson’s disease, progressive supranuclear palsy, thyrotoxic hypokalemic periodic paralysis, and type 1 diabetes). The only psychiatric finding was alcohol consumption and ALDH2 in individuals of East Asian ancestry.
be far more difficult than anticipated. Although we were hopeful that the initial GWAS might deliver insights, we created the PGC in order to hedge our bets; we needed a framework to aggregate data across studies with exceptional care and rigor if we were to progress. A critical step was to convince all groups that sharing individual data was essential—this is a foundational principle of the PGC and allows optimal quality control and analysis.

Moreover, to ensure progress, an “open science” perspective was required. Genome-wide summary statistics of all PGC analyses are available for widespread use (http://www.med.unc.edu/pgc), and the vast majority of PGC genotypic data that can be deposited are available to qualified researchers in a controlled-access repository. We recently have made available a list of the top loci from PGC analyses (both published and in preparation).

These early strategic decisions proved important, as results from the first wave of psychiatric GWAS, circa 2008, were unimpressive. Although we were careful not to hype GWAS (9, 10), some prominent commentators voiced strong doubts about its value—even though careful review of the early results showed unequivocal indications of genetic effects. The first-wave studies were simply underpowered, and combining studies to increase power was logical. Nevertheless, we persisted, and a 2012 letter signed by 96 psychiatric genetics investigators (“Don’t give up on GWAS”) anticipated the utility of GWAS should sample sizes increase (25).

To date, the PGC has published 24 main articles and 5 supplementary analysis articles (see Table S2). At least 141 additional papers have made use of PGC results. Many PGC papers are highly cited, but chief among them is the 2014 schizophrenia report (15), which ranks among the most highly cited articles in 2014. The PGC is among the leading genomics consortia worldwide for open science and data sharing. These successes are a testimony to the fact-based strategy and persistence of the PGC.

AN UPDATE

What have we learned? We now have a sizable body of empirical results relevant to the “common versus rare variant” debate. All common psychiatric disorders with sufficiently large samples have a predominant common disease/common variant contribution (26–28). Indeed, this is widely seen across human complex diseases, such as type 2 diabetes mellitus (29), and anthropometric traits, such as height (30) and body mass (31). Demonstrating a major role of common genetic variation in risk for human complex traits (including psychiatric disorders) is so widely and consistently documented that it is no longer particularly newsworthy.

There is a variable contribution of rare variation of strong effect. This tends to be larger for early-onset, severe disorders and lesser for disorders with normal-range developmental trajectories and adult onset (Figure 2A). However, even for psychiatric disorders with many proven examples of rare variants of strong effect (e.g., intellectual disability or early-onset Alzheimer’s disease), there is always a contribution of common variation. Rare variant studies have proven more difficult than anticipated, because to confidently identify rare variants of strong effect in typical clinical samples requires very large sample sizes, perhaps as many as around 100,000 cases (38). The protein-coding parts of the genome are replete with inconsequential variation, and current ways to predict functional consequences are imprecise (39). There is a lot of noise, and the signal is sparser and weaker than anticipated.

Figure 3C shows current sample sizes and notable findings for the PGC working groups. Schizophrenia has accumulated the most data for both common and rare variation. Figure 2B shows significant results from GWAS, copy number variation (CNV), and exome sequencing studies (15, 36, 37). Most findings are for common variation. Multiple rare CNVs have been implicated; most are multigenic, and all increase risk for several psychiatric disorders and neurological diseases (36). SETD1A is the only gene implicated to date by whole-exome sequencing studies (37), but other such studies have only found hints of biological pathways by focusing on extremely rare variation (40, 41). It was widely anticipated that exon variation in the 0.005 to 0.01 allele frequency range would be readily found, but this has not been observed (42), and a recent study of height required over 700,000 subjects to identify loci in this range (43). In a direct comparison, common variation had 14–28 times more impact on risk for schizophrenia than rare CNVs or rare exonic variation (44).

Another major finding has been the repeated empirical documentation of important genetic overlap (particularly common variation) among most or all adult- and childhood-onset psychiatric disorders (26, 27). It is clear that psychiatric nosology has not “carved nature at the joints.” Moreover, the common variant genetic architecture of many disorders blends into normal phenomena. For example, there are sizable genetic correlations of major depressive disorder with personality traits like neuroticism and readily assessed depressive symptom measures. Other findings suggest that reconceptualizations may be needed. For example, anorexia nervosa had a significant positive genetic correlation with schizophrenia, significant negative genetic correlations with body mass index and unfavorable metabolic measures, and significant positive genetic correlations with favorable metabolic factors. This pattern of findings suggests that the roots of anorexia nervosa may be not only psychiatric, but also metabolic, in origin.

The PGC work group on depression recently completed a report that identified 44 genetic loci for major depressive disorder (45). This work is notable because of the compressed time scale (2 months from final results to submission) as well as its demonstration of what the findings can tell us. The individual loci yielded multiple strong candidate genes (e.g., NEGR1, RBFOX1, and SOX5). The findings were associated with clinical features of depression (e.g., earlier age at onset and recurrent and more severe forms of depression). Gene expression patterns in the prefrontal and anterior cingulate cortex most closely matched the genetic findings (these brain
regions also show MRI differences between patients with major depression and control subjects). Genes that are targets of antidepressant medications were strongly enriched for depression association signals (p=8.5×10^{-10}), suggesting pharmacotherapeutic relevance. The genetic bases of lower educational attainment and higher body mass were putatively causal for major depressive disorder, whereas depression and schizophrenia reflected a partly shared biological etiology. This is an evolving area with regular increases in confident knowledge. To encourage rapid dissemination of results, the PGC regularly compiles and shares a list of the strongest findings for the disorders it studies.

**A CONSORTIUM AGENDA**

Attempts to understand the genetic basis of psychiatric disorders—to untangle and concretize the family history risk factor—have never been easy. However, by incorporating empirical results, a data-driven and logical way forward has emerged, and it is likely that these efforts will continue to yield important new knowledge. Many groups are active in this area, but the PGC has emerged as the key umbrella organization for a large portion of this work. A basic description of the PGC and its core principles is given in Figure 3A. Key technical aspects include its dedication to rigorous methodologies and its stance as a “mega-analysis” consortium with PGC members sharing individual-level genotype and phenotype data.

With continued support from the National Institute on Mental Health (NIMH) (and new support from the National Institute on Drug Abuse), the PGC recently initiated a program of research designed to deliver “actionable” findings, genomic results that 1) reveal the fundamental biology, 2) inform clinical practice, and 3) deliver new therapeutic targets. This is the central idea of the PGC: to convert the
FIGURE 3. Background, Current Projects, and Findings to Date of the Psychiatric Genomics Consortium (PGC)

A. BACKGROUND

General Information
- The PGC has been in continuous existence from 2007 to the present.
- The international membership includes over 800 scientists from 40 countries.
- The nine PGC working groups study attention deficit hyperactivity disorder, autism, bipolar disorder, eating disorders, major depressive disorder, obsessive-compulsive disorder/Tourette syndrome, posttraumatic stress disorder, schizophrenia, and substance use disorders. Provisional groups for anxiety disorders and Alzheimer’s disease were added in 2016.
- Current goals are to obtain genome-wide association data on 100,000 cases for each disorder.
- The PGC includes groups focused on cross-disorder analysis, copy number variation, statistical analysis, and pathway analysis.
- The PGC has published 24 main papers and 51 secondary analysis papers (see Table S2 in the data supplement accompanying the online version of this article). At least 141 papers have made use of PGC results.

PGC Core Principles
- Given the human, medical, and societal impact of psychiatric disorders, the PGC is passionate about rapid progress, and it is a world leader in data and results sharing.
- The PGC is characterized by open, inclusive, participatory, and democratic science.
- Core PGC activities are commercially ‘pre-competitive’: identifying the genomic results is a public good and part of the fundamental characterization of these psychiatric disorders.
- The PGC is committed to producing robust, replicable, and secure findings. Its work is based on rigorous methodology, a strong empirical focus, and healthy questioning of prior knowledge and assumptions.
- The PGC has a ‘mega-analysis’ framework: members share raw genotype data so that all samples can be processed using a uniform quality control, imputation, and analysis pipeline.

B. CURRENT PROJECTS

Common Genetic Variation: Continue and Expand PGC’s Ongoing Work to Increase Knowledge
1. GWAS. (a) The core business of the PGC: progressively larger GWAS mega-analyses for all disorders studied by the PGC. (b) Systematic cross-disorder analyses. (c) Pathway analyses to clarify biological implications. Critically, we have engaged academic and industry experts in psychopharmacology to maximize therapeutic implications of the findings.
2. Genetic risk scores. (a) Development: use data from large longitudinal cohorts to evaluate the developmental effects of genetic risk scores. (b) Clinical symptoms: analyze relationship between clinical descriptors and genetic risk scores to understand clinical relevance. (c) GxE: analyze interactions between genetic risk scores and environment.
3. Brainstorm initiative. Apply novel statistical methods to GWAS results to estimate pairwise genetic correlations among all PGC disorders and with all obtainable CNS-relevant diseases/quantitative traits (e.g., epilepsy, neuroimaging, personality, IQ) to develop a comprehensive portrait of genetic influences across a broad set of brain phenotypes.

Rare Variation: Enhance Discovery of Alleles With Larger Effects on Risk
4. Copy number variants (CNVs). Analyze rare CNVs in all PGC disorders via high-quality mega-analyses, and perform cross-disorder analyses to reveal pleiotropic genetic effects.
5. Sequencing. Characterize the full spectrum of genetic variation for schizophrenia (especially rare variants of strong effect) in regions implicated in Aim 1. Inexpensively sequence coding and regulatory regions of ~200 candidate genes in 20,000 independent subjects.
6. Pedigree sequencing. The large network of PGC clinicians has identified unusual pedigrees densely affected with psychiatric disorders. Systematically evaluate ~100 pedigrees for CNVs, high genetic risk scores, and whole-genome sequencing to enable searches for rare variants of strong effect.

C. FINDINGS TO DATE

<table>
<thead>
<tr>
<th>PGC Group</th>
<th>Cases</th>
<th>Hits</th>
<th>Twin $h^2$</th>
<th>SNP $h^2$</th>
<th>Notable Genetic Correlations</th>
</tr>
</thead>
<tbody>
<tr>
<td>Schizophrenia</td>
<td>60,995</td>
<td>155</td>
<td>81%</td>
<td>45%</td>
<td>Bipolar disorder</td>
</tr>
<tr>
<td>Major depressive disorder</td>
<td>130,664</td>
<td>44</td>
<td>30%–40%</td>
<td>8.9%</td>
<td>Worse sleep, greater body mass, and lower educational attainment</td>
</tr>
<tr>
<td>Bipolar disorder</td>
<td>20,352</td>
<td>19</td>
<td>80%</td>
<td>21%</td>
<td>Schizophrenia</td>
</tr>
<tr>
<td>Attention deficit hyperactivity</td>
<td>20,183</td>
<td>12</td>
<td>70%–80%</td>
<td>22%</td>
<td>Highest educational attainment</td>
</tr>
<tr>
<td>Autism spectrum disorder</td>
<td>18,381</td>
<td>3</td>
<td>75%</td>
<td>12%</td>
<td>Self-reported well-being</td>
</tr>
<tr>
<td>Anorexia nervosa</td>
<td>3,495</td>
<td>1</td>
<td>56%</td>
<td>~20%</td>
<td>Lower body mass and metabolic traits</td>
</tr>
<tr>
<td>Substance use disorders</td>
<td>12,798</td>
<td>1</td>
<td>50%</td>
<td>~8%</td>
<td>Smoking, alcohol consumption</td>
</tr>
<tr>
<td>Tourette syndrome</td>
<td>4,232</td>
<td>1</td>
<td>60%–80%</td>
<td>58%</td>
<td>OCD</td>
</tr>
<tr>
<td>Obsessive-compulsive disorder</td>
<td>2,688</td>
<td>0</td>
<td>45%–65%</td>
<td>37%</td>
<td>Tourette syndrome</td>
</tr>
<tr>
<td>Posttraumatic stress disorder</td>
<td>5,131</td>
<td>0</td>
<td>30%–40%</td>
<td>5%–35%</td>
<td>Schizophrenia</td>
</tr>
</tbody>
</table>

$^a$ Hits: independent associations reaching genome-wide significance. Twin $h^2$: heritability estimated from twin studies. SNP $h^2$: heritability estimated from results of genome-wide association studies (GWAS).

family history risk factor into biologically, clinically, and therapeutically meaningful insights. This program of research has six aims, three focused on common variation and three on rare variation (Figure 3B).
of sample sizes with time. Our goal is for each of the nine disorder working groups to obtain GWAS data on 100,000 cases. More information on case definitions can be found in Table S3 in the online data supplement.

Figure 4B encapsulates the experience with sample size and numbers of significant associations. Some disorders have a fortuitous architecture; for instance, inflammatory bowel disease obtained a considerable number of findings with relatively small samples. For most other complex traits, the path is slower but with sufficient samples discovery becomes linear. Figure 4C shows an idealized model of the sigmoid-like discovery process from “dead zone” to asymptote. We suggest that the goal is to get to a “good enough” point, where most genes are identified at least once and the majority of genes in salient biological processes are highlighted. This can provide an etiologic scaffold for studies that use other methods to identify interacting partners in gene networks and pathways that underlie pathogenesis. There may be on the order of 1,000 genes involved in schizophrenia (47) (for comparison, approximately 13,000 genes are expressed in the brain and about 2,000 at the synapse). Most of the nine PGC disorder working groups have identified at least one genome-wide significant association, several are accumulating moderate numbers of loci, and schizophrenia and major depression appear to be in the linear phase (Figure 3C).

The PGC has extended its initial efforts in three ways. First, we added four new and highly motivated groups (on eating disorders, obsessive-compulsive disorder/Tourette syndrome, posttraumatic stress disorder [PTSD], and substance use disorders). Provisional groups for anxiety disorders and Alzheimer’s disease have been formed. Second, we hope to markedly increase inclusion of non-European samples (see Figure S1 in the online data supplement). For example, the PGC is now completing a report based on over 12,000 schizophrenia cases from East Asia. The PTSD and substance use disorders groups are studying increasingly larger samples of African Americans. The Stanley Center of the Broad Institute has launched major sample collection efforts for multiple severe psychiatric disorders in Africa, South America, and Asia.

This work is crucial for generalizability. Although it is likely that most (but not all) associations will be observed across the world, there will also be population differences, and it is clear that the application of genetic risk scores globally (see next paragraph) will require risk allele weights derived from the major ancestral populations. Finally, the PGC has engaged academic and industry experts to understand the therapeutic salience of the findings (48). Indeed, the empirical targets of antipsychotic medications are markedly enriched for the results of schizophrenia GWAS, and this enrichment became clearer with increasing sample sizes, as has the potential pharmacological relevance of calcium channels for psychiatry (49). The design of rational therapeutics has been an elusive goal for psychiatric indications, and improved genomic knowledge is a precompetitive activity that can make novel drug discovery more efficient (50).

Aim 2. Aim 2 concerns the analysis of genetic risk scores. For a complex disease or trait, the genetic risk score is a single, normally distributed variable that captures the cumulative effect of risk alleles inherited by an individual (e.g., for schizophrenia, bipolar disorder, or body mass index). Computing a genetic risk score requires a training set (i.e., GWAS results) and genome-wide genotypes for independent test subjects (e.g., a population cohort or participants in a clinical trial). The PGC has made training sets publicly available for multiple disorders. This allows researchers to compute genetic risk scores for whatever use they deem appropriate. These scores are not yet sufficiently discriminating to be useful clinically (15) but are among the first demonstrably valid biomarkers for psychiatric disorders. Genetic risk scores derived from PGC results have been widely used in psychiatric research for generating patient strata, exploring diagnostic boundaries, identifying cognitive and behavioral correlates of genetic risk that predate clinical disorders, and evaluating the validity of putative cognitive or imaging phenotypes (51). Many social scientists have embraced the approach, seeing opportunities to study how genetic factors interact with the social environment (e.g., socioeconomic status) to influence health and broader outcomes (52).

The PGC will systematically evaluate genetic risk scores in three contexts: 1) development—use data from large longitudinal cohorts to evaluate the developmental effects of genetic risk scores; 2) clinical—analyze the relationship between clinical descriptors/symptoms (e.g., early versus late onset, more severe versus milder, or unremitting versus episodic illness) and the genetic risk score to understand clinical relevance; and 3) environment—analyze interactions between the genetic risk score and environmental variables in epidemiological samples.

Aim 3. Aim 3 will use GWAS results to estimate pairwise genetic correlations among all PGC disorders with all obtainable CNS-relevant diseases and quantitative traits (e.g., epilepsy, neuroimaging, personality, and cognition). We will develop a comprehensive portrait of genetic influences across a broad set of brain phenotypes with the intention of improving nosology.

Past epidemiological studies have documented the extensive comorbidities of psychiatric disorders at the phenotype level. Due to limitations inherent to observational studies, understanding whether a phenotypic correlation is potentially causal or if it results from reverse causation or confounding is generally difficult or impossible. Genetic studies now offer complementary strategies. We can readily assess whether a phenotypic association between psychiatric disorders or between a psychiatric disorder and a risk factor is mirrored by a common variant genetic correlation. This can be done using GWAS summary statistics. If the genetic studies are sufficiently large, it is also possible to apply Mendelian randomization to evaluate the potential causality of the association (53).
FIGURE 4. GWAS Sample Sizes and Rates of Discovery in Psychiatric Genomics Consortium (PGC) Studies

A. Numbers of cases for GWAS analyses

B. Relation between numbers of cases and genome-wide significant SNPs in GWAS

C. Hypothetical relation between numbers of cases and genome-wide significant associations for a human complex disease or trait

For the original five PGC disorders (ADHD to schizophrenia), the three bars represent the numbers of cases in the initial reports (PGC1), the next round of papers (PGC2), and the projected numbers by 2019 (PGC3). For the four disorders added in 2013 (eating disorders to substance use disorders), the PGC2 and projected PGC3 numbers are shown.

Inflammatory bowel disease has an exceptional genetic architecture and excellent clinical diagnostic specificity, which enabled considerable discovery with relatively smaller numbers of cases. Schizophrenia, height, and bipolar disorder follow more typical and approximately similar discovery paths.

There is an initial dead zone whose length depends on how many cases are accrued and the largest effect size. This is followed by an inflection point where the significant associations begin to accumulate and then a linear phase. Complexities arising from the true nature of the initially unknown genetic architecture could change the form of this curve in important ways.
For example, a recent PGC study reported sizable positive genetic correlations between major depressive disorder and multiple measures of body mass (45). We investigated the association by using bidirectional Mendelian randomization and found evidence suggesting a potential genetic causal effect of body mass on risk for depression but not the reverse. These results provide hypotheses for more detailed prospective studies, and the underlying mechanisms are likely to be more complex.

We will operationalize similar analyses for other disorders (e.g., autism with/without intellectual disability, bipolar disorder with/without psychosis or with/without lithium response). Given sex differences in disease prevalence for many disorders, analyses of genetic correlations by sex will be conducted as well. In addition, many of these disorders have significant genetic correlations with cognition, personality, and body mass. Are these genetic correlations putatively causal or due to some other process (confounding or bias)? Differences between disorders will be investigated—for example, body mass has a positive genetic correlation with major depression but a negative genetic correlation with anorexia nervosa (54).

Aims of Work on Rare Genetic Variation

**Aim 4.** Aim 4 will continue the PGC’s CNV efforts (36). The PGC CNV group has created a pipeline to determine the presence or absence of CNVs from the initial intensity files by using multiple algorithms followed by careful quality control and analysis. The initial schizophrenia paper has been published, and this group is now working on bipolar disorder, ADHD, and PTSD and will include more groups with time.

**Aim 5.** Aim 5 is a “cheap-seq” aim. We will conduct inexpensive (approximately $50/subject) schizophrenia-focused sequencing of 200 genes in 20,000 subjects. Genes will be selected based on all available sequencing results. For 200 genes, we will increase power far more cost-effectively than with whole-exome (10 times cheaper) or whole-genome (25 times cheaper) sequencing in the same time frame. We propose an efficient and affordable way to markedly increase sample sizes for the most promising loci in a new sample of 20,000 subjects.

**Aim 6.** Aim 6 will systematically evaluate approximately 100 large pedigrees to search for genetic variants of large effect. We have engaged the large network of PGC clinicians in this task. Most experienced clinicians have encountered unusual pedigrees with high concentrations of severe psychiatric disorders. For example, one pedigree has more than 100 individuals with a severe psychiatric disorder, and eight pedigrees have 20 or more affected individuals. Other pedigrees are from genetic isolates in which marriage between relatively close relatives is common. Still other pedigrees have extensive comorbidity with intellectual disability and epilepsy. No one has systematically and comprehensively evaluated a large collection of densely affected pedigrees using comprehensive genomic assays (karyotyping, identity by descent, CNVs, whole genome sequencing, and genetic risk score) combined with a rigorous statistical framework. However, a pedigree very dense with psychiatric disorders can occur because a rare variant of strong effect is segregating in that pedigree or because that pedigree has an unusually high number of common variants of small effect (see reference 55 for an example).

**Actionability**

Among the aims related to common variants, aim 1 is of biological, clinical, and therapeutic relevance. Aims 2 and 3 are important clinically and for nosology. Of the rare variant aims, all are important biologically and therapeutically (given their potential to identify single genes whose mutational disruption carries high risk).

**ISSUES IN THE PROCESS OF BEING SOLVED**

Empirical results from psychiatric genomics have begun to answer many fundamental questions. We point to two major unresolved issues. First, a crucial issue is pinpointing the biological implications of GWAS results. What precise mechanistic hypotheses arise from the findings? If a GWAS “associates” a psychiatric disorder with a specific genomic region, what genes should neuroscientists and molecular biologists study in order to delve more deeply into the basis of a disorder? This is crucial for downstream experimentation, as studying one gene in detail can easily consume several person-years and hundreds of thousands of dollars.

Making connections from DNA sequence variation to a cellular mechanism is sometimes straightforward. This is one reason researchers like to exploit rare exon variants (Aims 5 and 6), as the connection to a gene is usually direct and can be logically evaluated with some confidence. Occasionally, common variant findings can be directly implicated; for example, the PGC major depression study found two separate associations on opposite sides of the same gene (RBFOX1) (45).

However, such findings are unusual for many common psychiatric disorders (Figure 2), and connecting the numerous common variant association signals to genes can be challenging. Figure 5 illustrates typical patterns of results. Figure 5A shows the CACNA1C intronic association for schizophrenia; a subsequent study suggested that these variants interact with a regulatory element for CACNA1C (56). Figure 5B depicts the region surrounding DRD2 (encoding a key target of antipsychotics). This association has been functionally connected to DRD2 via DNA-DNA regulatory loops (57). Figure 5C shows a multigenic region—the association region covers many brain-expressed genes associated with multiple human traits. Figure 5D depicts a region associated with schizophrenia but far from any known protein-coding gene.

These are typical for GWAS results. Although localization is imprecise, the associated genomic regions are clearly
informative as they implicate salient biological pathways (58), specific genomic features (59), and targets of common psychiatric medications (45, 49). Connecting most or all of the findings to specific genes requires additional data based on the function of the human brain, e.g., brain gene expression in brain regions (60), DNA-DNA looping (57), and epigenomics (61). NIMH has funded the PsychENCODE consortium (61) to conduct an array of functional genomic assays on brain samples from people with severe psychiatric disorders to enable this work. We anticipate considerable progress in this area in the near future.

Second, as discussed above, the genetic basis of most psychiatric disorders shows fundamental connections. For example, the common variant genetic basis of major psychiatric disorders is illustrated in FIGURE 5. Examples of Genomic Regions Significantly Associated With Schizophrenia.

![FIGURE 5. Examples of Genomic Regions Significantly Associated With Schizophrenia](image)

a Examples of genome-wide significant regions for schizophrenia with tracks showing the location (hg19), genes in the region, GWAS results from the literature, and the schizophrenia results (one green vertical bar per SNP, height corresponds to $-\log_{10}(p\text{ value})$ with 7.3 equivalent to $5 \times 10^{-8}$).
depressive disorder overlaps significantly with those for anxiety disorders, autism, ADHD, schizophrenia, bipolar disorder, smoking behavior, and anorexia nervosa (45). Moreover, the presence or absence of some clinical disorders (major depression, autism, and ADHD) shows strong genetic overlap with the analogous symptoms in general population samples. Further, the common genetic basis of many psychiatric disorders is often strongly correlated with that of putative subphenotypes (also known as endophenotypes or component phenotypes). For example, the common variant genetic basis of major depression is correlated with that for worse sleep, higher neuroticism, and greater body mass in people without major depression (45). These results strongly suggest that our diagnostic categories do not define pathophysiological entities. The resolution of these issues will address major unanswered questions: From a genetic perspective, what are these disorders? How are they similar and how are they different?

COMMON COMPLAINTS

Briefly, there are three common complaints about the work of the PGC. First, “The results don’t matter”—the readouts are broad and the effect sizes of individual associated loci are small. In fact, as discussed above, the results are delivering increasingly useful and targeted knowledge (discussed above in the section on aim 1) (48, 49, 58). The small effect sizes do not constrain the potential utility of targeting the identified genes or pathways—drugs targeting those pathways can have major effects. Small effects can identify “druggable” targets; the canonical example of this is the identification by GWAS of common genetic variation of small effect for multiple cholesterol measures in a gene (HMGCR) whose protein is the target of a class of cholesterol-lowering medications (50). Pharmaceutical companies are now following this area closely as genomic data are increasingly crucial to drug development (50).

Second, “What about unaccounted heritability (h²)?” Heritability estimated from genome-wide single nucleotide polymorphism data (SNP-h²) depends on technical issues and especially sample size. The comparator is estimated from imprecise twin or family data (twin-h² or pedigree-h²). “Unaccounted h²” refers to the difference between these estimates and attempts to reconcile fundamentally different entities. Still, when the genomic study is sufficiently large (as with schizophrenia), SNP-h² is around half of the pedigree-h². A point often missed, however, is that explaining h² is a minor goal. The main goals of the PGC are to gain biological, clinical, and therapeutic insights, which can arise regardless of the magnitude of heritability accounted for.

Third, because most PGC analyses are based on categorical, case versus control analyses, “PGC cases lack clinical depth.” This was by intention: over 10 years ago (47), some of us reasoned that fast phenotype characterization that led to affordable large sample sizes was the logical first step (as opposed to large numbers of phenotypes on small numbers of subjects). This was always the first step. The success of this strategy is seen not only in the genome-wide significant loci that we have discovered, but also in the many phenotypes that have been associated with PGC genetic risk score in both clinical and population samples. The second step, under way now, is detailed characterization of genetically informative subsets of cases (e.g., aim 2). In addition, some PGC working groups (e.g., substance use disorders) are currently analyzing quantitative phenotypes.

CONCLUSIONS

The PGC is the largest and most systematic genomics effort in the history of psychiatry. In the next 5 years, we propose to markedly scale up our work. By tackling nature as it is and not as we might want it to be, we hope to provide considerable new knowledge about the fundamental basis of psychiatric disorders. Our long-standing commitment to global collaboration, open science, and rapid progress means that we will make our results and tools available in a timely manner. Prediction of the future is always hazardous, but given that we finally have a minimally adequate toolkit for genomics, it is possible that we are entering a golden age of research into the fundamental basis of severe mental illness.

AUTHOR AND ARTICLE INFORMATION

From the Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm; the Departments of Genetics, Psychiatry, and Nutrition, University of North Carolina, Chapel Hill, N.C.; the Department of Psychiatry, Washington University School of Medicine, St Louis; the Norwegian Centre for Mental Disorders Research (NORMENT), K.G. Jebsen Centre for Research on Neuropsychiatric Disorders, University of Oslo and Oslo University Hospital, Oslo; the Lundbeck Foundation Initiative for Integrative Psychiatric Research (PSYCH), Aarhus University, Aarhus, Denmark; the Department of Biomedicine—Human Genetics, Aarhus University, Aarhus, Denmark; the Institute of Psychiatry, Psychology and Neuroscience, MRC Social, Genetic and Developmental Psychiatry Centre, King’s College London, London; the National Institute for Health Research Biomedical Research Centre, South London and Maudsley National Health Service Trust, London; the Division of Medical Genetics, Department of Biomedicine, University of Basel, Basel, Switzerland; the Institute of Human Genetics, University of Bonn, Bonn, Germany; the Department of Genomics, Life and Brain Center, Bonn, Germany; the Institute of Neuroscience and Medicine, Juelich, Germany; the Department of Biochemistry and Molecular Biology, Indiana University School of Medicine, Indianapolis; the Departments of Psychiatry and of Neuroscience and Physiology, SUNY Upstate Medical University, Syracuse, NY.; the Department of Psychiatry, Yale University, New Haven, Conn.; the Department of Psychiatry and the Genetics Institute, University of Florida, Gainesville; the Department of Psychiatry, University of California—San Diego, La Jolla, Calif., the Psychiatric and Neurodevelopmental Genetics Unit, Center for Genomic Medicine, and the Department of Psychiatry, Massachusetts General Hospital, Boston; the Stanley Center for Psychiatric Research, Broad Institute of MIT and Harvard, Cambridge, Mass.; and the MRC Centre for Neuropsychiatric Genetics and Genomics, Institute of Psychological Medicine and Clinical Neurosciences, School of Medicine, Cardiff University, Cardiff, U.K.

Address correspondence to Dr. Sullivan (jfsullivan@med.unc.edu).

The Psychiatric Genomics Consortium Coordinating Committee comprises Mark Daly, Michael Gill, John Kelsoe, Karestan Koenen, Douglas Levinson, Cathryn Lewis, Ben Neale, Danielle Posthuma, Jonathan Sebat, and Pamela Sklar.
The Psychiatric Genomics Consortium (PGC) has received major funding from the National Institute of Mental Health and the National Institute on Drug Abuse (PGC3: U01 MH109528 and U01 MH109532, PGC2: U01 MH094421, PGC1: U01 MH085520). Dr. Agrawal is also supported by grant K02 DA32573 from the National Institute on Drug Abuse. Other significant funders include the Lundbeck Foundation, Stanley Center of the Broad Institute, Science Foundation Ireland, Cohen Veterans Bioscience, Norwegian Institute of Health, and Klarman Family Foundation. Dr. Farraone is supported by the K.G. Jebsen Centre for Research on Neuropsychiatric Disorders, University of Bergen, Bergen, Norway; the European Union’s Seventh Framework Programme for research, technological development, and demonstration under grant agreement 602805; the European Union’s Horizon 2020 research and innovation program under grant agreement 667302; and NIMH grants R01MH101519 and U01 MH109536–01.

The authors thank the investigators of the Psychiatric Genomics Consortium and the hundreds of thousands of people who have shared their life experiences with consortium investigators.

Dr. Sullivan is a scientific advisor for Pfizer and Lundbeck and received an honorarium from F. Hoffmann-La Roche. Dr. Bulik is a consultant for and grant recipient from Shire and is a member of its Scientific Advisory Board; she also receives royalties from Pearson and from Walker. Dr. Andreassen received a speaker’s honorarium from Lundbeck in 2016 and has received research grants from the Research Council of Norway. Dr. Berglum has received research grants from the Lundbeck Foundation supporting the Lundbeck Foundation Initiative for Integrative Psychiatric Research, iPSYCH (grants R102–A9118 and R155–2014–1724). Dr. Breen has received speaking fees from Illumina and grant funding from Eli Lilly. Dr. Cichon is principal investigator on an investigator-initiated study with Actelion Pharmaceuticals (project title: NGS-based detection of rare mutations in NPC1 and NPC2 genes in patients with schizophrenia). In the past year, Dr. Farraone received income, potential income, travel expenses, continuing education support, and/or research support from Lundbeck, Rhodes, Arbor, KenPharm, Ironshore, Shire, Akili Interactive Labs, CogCubed, Alcobra, VAYA, Sunovion, Genomind, and NeuroLifeSciences; with his institution, he holds U.S. patent US20130217707 A1 for the use of sodium-hydrogen exchange inhibitors in the treatment of ADHD; in previous years, he received support from Shire, Neurovance, Alcobra, Otsuka, McNeil, Janssen, Novartis, Pfizer, and Eli Lilly; he receives royalties from books published by Guilford Press (Straight Talk About Your Child’s Mental Health), Oxford University Press (Schizophrenia: The Facts), and Elsevier (ADHD: Non-Pharmacologic Interventions); and he is principal investigator with ADHD in Adults (www.adhdinadults.com). Cardiff University received an honorarium from F. Hoffmann-La Roche for a presentation by Dr. O’Donovan in 2015. Multiple drug companies work with the Psychiatric Genomics Consortium in a manner equivalent to that of academic investigators. The other authors report no relationships with commercial interests.

Received March 9, 2017; revision received May 8, 2017; accepted May 15, 2017; published online October 3, 2017.

REFERENCES


6. Wray NR, Gottesman II: Using summary data from the Danish national registers to estimate heritabilities for schizophrenia, bipolar disorder, and major depressive disorder. Front Genet 2012; 3:118


17. Wellcome Trust Case Control Consortium: Genome-wide association study of 14,000 cases of seven common diseases and 3,000 shared controls. Nature 2007; 447:661–678


44. Major Depressive Disorder Working Group of the Psychiatric Genomics Consortium: Genome-wide association analyses identify 44 risk variants and refine the genetic architecture of major depressive disorder. http://www.biorxiv.org/content/early/2017/07/24/167577